Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived, according to clinical researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Brigham and Women's Hospital. This is comparable to the rate of eventual pregnancy among all clinically infertile women.

15 Jul 2013

Genetic abnormality linked to cancer four times more common in people with type 2 diabetes

A type of genetic abnormality linked to cancer is more common in people with type 2 diabetes than the rest of the population, a new study has found.

15 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

High-resolution mapping of the epigenome has discovered unique patterns that emerge during the generation of brain circuitry in childhood.

6 Jul 2013

Findings uncover epigenomic modification that occurs during brain formation

Changes in the epigenome, including chemical modifications of DNA, can act as an extra layer of information in the genome, and are thought to play a role in learning and memory, as well as in age-related cognitive decline.

5 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Scientists examine molecular similarities in human and canine B-cell lymphoma

Humans and their pet dogs are close, so close that they both develop a type of cancer called diffuse large B-cell lymphoma. In humans it's the most common lymphoma subtype while in dogs, it's one of the most common cancers in veterinary oncology.

26 Jun 2013

Researchers discover promising new way to treat HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

26 Jun 2013

New study provides guidelines for stem cell transplantation in older MDS patients

A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Lymphoma News and Research

Further Reading

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Genetic abnormality linked to cancer four times more common in people with type 2 diabetes

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

Findings uncover epigenomic modification that occurs during brain formation

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

Researchers study possible alternative medications to treat cancer-related pain

Scientists examine molecular similarities in human and canine B-cell lymphoma

Researchers discover promising new way to treat HIV-related blood cancer

New study provides guidelines for stem cell transplantation in older MDS patients

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News